Edgewise Therapeutics Welcomes Accomplished Cardiologist Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

Edgewise Therapeutics Inc. (NASDAQ: EWTX) is pleased to announce the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox is an esteemed leader in clinical development and regulatory strategy, currently serving as President and CMO at BridgeBio Pharma and previously as CMO at MyoKardia. While at MyoKardia, Dr. Fox co-invented Camzyos® (mavacamten), an innovative treatment for obstructive hypertrophic cardiomyopathy (oHCM). His expertise will be immensely valuable to Edgewise as it focuses on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders.

We are delighted to bolster our cardiovascular expertise with the addition of Jonathan to our Board of Directors. His vast experience and expertise in cardiovascular clinical development and product approvals will be a tremendous asset as we move our groundbreaking EDG-7500 cardiac program towards a Phase 1 trial for Hypertrophic Cardiomyopathy in the second half of 2023.

Dr. Fox is highly impressed by Edgewise’s innovative and advanced scientific platform which has the potential to drastically improve the lives of individuals suffering from severe and progressive muscle disorders. EDG-7500 is a remarkable investigational therapy for the treatment of HCM, with a unique mechanism of action that could revolutionize the field.

Dr. Fox is no stranger to the world of biotechnology and medicine. He currently serves as President and CMO for cardiovascular and renal diseases at BridgeBio Pharma, a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, he was the CMO of MyoKardia, Inc. from 2013 to 2016, as well as a consultant at Nigel-Montgomery from 2012 to 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca from 1998 to 2012. He also held a faculty position at the University of Pennsylvania School of Medicine from 1993 to 2013 and currently serves as an adjunct faculty member at the Stanford University Cardiovascular Institute. Additionally, Dr. Fox is a board member of ML BioSolutions and a trustee of the Lankenau Institute for Medical Research. He obtained his A.B. in biology, his Ph.D. in medicine and pathology and his M.D. from the University of Chicago, followed by Internal Medicine and Cardiology training at Duke University. His impressive credentials include ABIM Certification in Cardiovascular Diseases and Fellowship of the American College of Cardiology.

About Edgewise Therapeutics

Dr. Fox is absolutely astounded by Edgewise’s pioneering and cutting-edge scientific platform, which has the capability to drastically enhance the lives of those with intense and progressive muscle conditions. EDG-7500 is an incredible investigational therapy for the treatment of HCM, with a groundbreaking mode of action that could be a game-changer in the field.

Leave a Comment